Clinical Trial Update: Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating a four-drug combination (vemurafenib, cobimetinib, atezolizumab, and tiragolumab) for high-risk stage III cutaneous melanoma; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Cobimetinib (cobimetinib)
• Tiragolumab (tiragolumab)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Mayo Clinic | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING